Abstract
Background: Dextran (DX) is a natural polysaccharide produced in the laboratory by fermentation of sucrose under the effect of the enzyme DX sucrase (1,6-α-D-glucan-α- glucosyltransferase). After harvesting and purification DX is subjected to cracking and separation to obtain the desired molecular weight. Methods: The hydroxyl groups present in DX offer many sites for derivatization allowing the production of functionalized glycoconjugates biocompatible compound. DX and its derivatives are getting increased attention for use in core decoration or as carriers in novel drug delivery systems. This includes, among others, ion-pairing, self-aggregate, protein and drug conjugates. DX carriers and camouflaged particles will be dealt with in this review to give emphasis on the great versatility of this natural biocompatible polysaccharide. Conclusion: With the continuous development in the area of drug delivery, we believe that the unique properties of this versatile nanocarrier platform will elect it as one of the cornerstones of safe nanodelivery systems.
Keywords: Dextran, amphiphiles, conjugates, ion pairing, ionic complexation, layer-by-layer, stabilizer, self-assembly.
Current Pharmaceutical Design
Title:Dextran-based Nanocarriers for Delivery of Bioactives
Volume: 22 Issue: 22
Author(s): Rania A.H. Ishak, Rihab Osman and Gehanne A.S. Awad
Affiliation:
Keywords: Dextran, amphiphiles, conjugates, ion pairing, ionic complexation, layer-by-layer, stabilizer, self-assembly.
Abstract: Background: Dextran (DX) is a natural polysaccharide produced in the laboratory by fermentation of sucrose under the effect of the enzyme DX sucrase (1,6-α-D-glucan-α- glucosyltransferase). After harvesting and purification DX is subjected to cracking and separation to obtain the desired molecular weight. Methods: The hydroxyl groups present in DX offer many sites for derivatization allowing the production of functionalized glycoconjugates biocompatible compound. DX and its derivatives are getting increased attention for use in core decoration or as carriers in novel drug delivery systems. This includes, among others, ion-pairing, self-aggregate, protein and drug conjugates. DX carriers and camouflaged particles will be dealt with in this review to give emphasis on the great versatility of this natural biocompatible polysaccharide. Conclusion: With the continuous development in the area of drug delivery, we believe that the unique properties of this versatile nanocarrier platform will elect it as one of the cornerstones of safe nanodelivery systems.
Export Options
About this article
Cite this article as:
A.H. Ishak Rania, Osman Rihab and Awad A.S. Gehanne, Dextran-based Nanocarriers for Delivery of Bioactives, Current Pharmaceutical Design 2016; 22 (22) . https://dx.doi.org/10.2174/1381612822666160209152329
DOI https://dx.doi.org/10.2174/1381612822666160209152329 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prospects of Molecularly-Targeted Therapies for Cervical Cancer Treatment
Current Drug Targets Peroxisome Proliferator Activated Receptor α Ligands as Anticancer Drugs Targeting Mitochondrial Metabolism
Current Pharmaceutical Biotechnology Modulation of Expression and Activity of ABC Transporters by the Phytoestrogen Genistein. Impact on Drug Disposition
Current Medicinal Chemistry Molecular Mechanisms Underlying Psychological Stress and Cancer
Current Pharmaceutical Design Testicular Germ Cell Tumors: A Paradigm for the Successful Treatment of Solid Tumor Stem Cells
Current Cancer Therapy Reviews Role of the Renin-Angiotensin System in Gynecologic Cancers
Current Cancer Drug Targets Genetic Alterations in Differentiated Thyroid Cancers
Endocrine, Metabolic & Immune Disorders - Drug Targets Angiogenesis Markers in Gynecological Tumors and Patents for Anti- Angiogenic Approach: Review
Recent Patents on Anti-Cancer Drug Discovery Kisspeptin: Paving the Way to a New Therapeutic Avenue in Reproduction
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Bioinformatics of Protein-Protein Interfaces and Small Molecule Effectors
Current Bioinformatics Potential New Anticancer Molecular Targets for the Treatment of Human Testicular Seminomas
Mini-Reviews in Medicinal Chemistry Melatonin in Pregnancy: Effects on Brain Development and CNS Programming Disorders
Current Pharmaceutical Design Suppressing Glioblastoma Stem Cell Function by Aldehyde Dehydrogenase Inhibition with Chloramphenicol or Disulfiram as a New Treatment Adjunct: A Hypothesis
Current Stem Cell Research & Therapy Recent Patents on Alphavirus Protein Expression and Vector Production
Recent Patents on Biotechnology An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs
Current Topics in Medicinal Chemistry Recent Advances in the Development of Casein Kinase 1 Inhibitors
Current Medicinal Chemistry Fungal Proteins with Antiproliferative and Anticancer Activities
Protein & Peptide Letters Gonadotropin-Releasing Hormone Receptor Signaling: Biased and Unbiased
Mini-Reviews in Medicinal Chemistry Recent Developments of Flavonoids with Various Activities
Current Topics in Medicinal Chemistry Natural Products Based Anticancer Agents
Mini-Reviews in Organic Chemistry